A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.

Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.

The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.

A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.